Want to see COLL full AI Analyst Report?
EarningsQ2 2026 Earnings Report
COLL Q2 2026 EPS Results
Actual EPS$1.92
Consensus EPS$1.72
Beat/MissBeat by +$0.20
One Year Ago EPS$1.68
COLL Q2 2026 Revenue Results
Actual Revenue$199.88M
Expected Revenue$199.63M
Beat/MissBeat by +$253.00K
YoY Revenue Growth+6.32%
Earnings Announcement Details
QuarterQ2 2026
Date08/06/2026
TimeBefore Open
Conference CallThursday, August 6, 2026
COLL Upcoming Earnings
Collegium Pharmaceutical's next earnings date is estimated for November 5, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
COLL Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlighted strong, accelerating growth in the ADHD franchise—Jornay PM momentum, the strategic Azstarys acquisition with early revenue and raised guidance, Belbuca growth and incremental formulary wins, and an 8% increase in adjusted EBITDA. Offsetting these positives were meaningful declines in the NUCYNTA franchise driven by authorized generic pricing, a decline in Xtampza ER, a GAAP net loss driven by acquisition-related costs, substantial cash deployed to acquire Azstarys and a modest leverage increase, and potential LOE risk for Belbuca. Overall, management presented a constructive outlook focused on ADHD-led growth and disciplined capital deployment while acknowledging near-term pain portfolio pressures and one-time acquisition impacts.Company Guidance
Jornay PM Prescription and Revenue Growth
Jornay PM prescriptions grew 13.1% year-over-year; net revenue for Jornay PM was $46.1 million in Q2, up 41% year-over-year. Prescribers exceeded 30,000 (up 17.6% YoY).
Market Share Gains for Branded Long-Acting Methylphenidate
Share of the branded long-acting methylphenidate market increased to 29.2%, up 5.8 percentage points year-over-year.
Strong Segment Growth by Age Group
Pediatric/adolescent prescriptions (≈80% of business) grew 10.7% YoY; adult segment (≈20%) grew 23% YoY.
Azstarys Acquisition and Early Commercial Performance
Completed acquisition of Azstarys in May; initial Azstarys revenue was $12.9 million (~1.5 months of sales). Management raised full-year Azstarys guidance to $65M–$75M and reported IP protection through 2037. Integration complete and sales force expanded (≈190 reps) with target HCPs increased to ~27,000.
Pain Portfolio Durability and Belbuca Momentum
Pain portfolio generated $140.9 million in quarterly revenue; Belbuca revenue was $57.7 million, up 10% YoY. Belbuca secured formulary access to an additional 9 million lives effective Q4.
Company-Level Revenue and Profitability (Non-GAAP)
Total net product revenues were $199.9 million in Q2, up 6% YoY. Non-GAAP adjusted EBITDA was $113.8 million, up 8% YoY. Non-GAAP adjusted EPS was $1.92 vs $1.68 prior-year quarter.
Updated Full-Year Revenue Guidance and Stability of Jornay PM Outlook
Jornay PM full-year guidance unchanged at $190M–$200M. Company updated total product revenue guidance to $825M–$855M (midpoint ~8% YoY increase) and expects Azstarys to contribute $65M–$75M.
Cash Generation and Capital Deployment
Operating cash flow in Q2 was $71.3 million. Company retains financial flexibility (cash, cash equivalents and marketable securities $129.5M as of June 30) and is executing a disciplined capital deployment strategy (acquisition, debt paydown, opportunistic buybacks).
Commercial and Organizational Recognitions
Positive HCP market research: Jornay PM ranked #1 in product differentiation; 70% of HCPs indicated intent to increase prescribing. Company recognized as a 2026 Best Places to Work (Boston Business Journal) and USA Today Top Workplaces.
COLL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed